Teva Pharmaceutical Industries Ltd. announced interim data from a prospective, open label survey study evaluating spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to Copaxone® (glatiramer acetate injection) from interferon-beta treatment. These data were presented today at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans, Louisiana.
Interim results for the first 52 of 110 participants revealed a significant reduction in muscle stiffness, pain and discomfort, as well as the effect of spasticity on the ability to walk, body movements and activities of daily living (ADLs). Improvement was also found in reduction of total spasticity scores during the six month period.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767